It has been suggested that a sustained virologic response (SVR) can be achieved in patients infected with hepatitis C virus (HCV) of genotype 2 or 3 with a shorter duration of pegylated interferon ...
Please provide your email address to receive an email when new articles are posted on . Roche Diagnostics announced the release of new assays for HIV-1, hepatitis C virus infection and genotyping ...
April 27, 2010 (Vienna, Austria) — Adding nitazoxanide (Alinia, Romark Laboratories) to standard therapy helped boost sustained virologic response (SVR) rates for some hepatitis C virus (HCV) genotype ...
(HealthDay News) — Worldwide, genotype 1 is the most prevalent variant of hepatitis C virus (HCV) infections and accounts for almost half of cases, according to research published online July 28 in ...
The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus genotype 3 infections. The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C ...
GENT, Belgium--(BUSINESS WIRE)--Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc.
The Abbott Real Time HCV Genotype II test, the first genotyping test for hepatitis C patients, has received FDA approval, according to a Medscape report. The test, created by Des Plaines, Ill.-based ...
Viekira Pak is indicated for chronic hepatitis C virus (HCV) genotype 1 infection. Viekira Pak is indicated for chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin. Product ...
Gilead Sciences announced results from ION-4, a Phase 3 study evaluating Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for the treatment of genotypes 1 or 4 chronic hepatitis C virus (HCV) infection ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. New data from the GARNET study — presented today in ...
The FINANCIAL — Roche announced on November 3 the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark. These new molecular diagnostic ...